• Explore /
  • Poster
  • / Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

Abstract Poster

Authors

null

Ignacio Melero Bermejo

Clinica Universidad de Navarra, Pamplona, Spain

Ignacio Melero Bermejo , Elizabeth M. Jaffee , Diwakar Davar , Josephine Cardarelli , Daphne Williams , Penny Phillips , Michael Carleton , Ming Zhou , Olivier De Henau , Manish Monga , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03400332

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3109)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3109

Abstract #

TPS3109

Poster Bd #

319a

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.

Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.

First Author: Michael Carleton

First Author: Reinhard Dummer

First Author: Jordi Rodon Ahnert

First Author: S. Rubina Baglio